Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study,by Kim M,Kim TH,Shin DY,Lim DJ,Kim EY,Kim WB,Chung JH,Shong YK,Kim BH,and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG). Thyroid 2018;28(3)340–348. DOI: 10.1089/thy.2017.0356

In the March 2018 issue of Thyroid (vol. 28, no.3; 340–348), the article entitled “Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study” by Kim et al. requires correction.

The first two authors of this article, Mijin Kim and Tae Hyuk Kim, share co-first authorship. The authors should appear as:

Mijin Kim,^1,* Tae Hyuk Kim,^2,* Dong Yeob Shin,³ Dong Jun Lim,⁴

Eui Young Kim,⁵ Won Bae Kim,¹ Jae Hoon Chung,² Young Kee Shong,¹

Bo Hyun Kim,⁶ and Won Gu Kim¹ on behalf of Korean Thyroid Cancer Study Group (KTCSG)

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

²Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

³Division of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

⁴Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

⁵Department of Endocrinology, Dongnam Institute of Radiological and Medical Sciences Cancer Center, Busan, Korea.

⁶Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.

*Co-first authors.

The online version of the article has been corrected to reflect this change.